Androgen
Deprivation Therapy (ADT) Market, by Drug Class (Antiandrogens, LHRH
Agonists, LHRH Antagonist, and Others), by Route of Administration (Oral and
Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies,
and Online Pharmacies), and by Region (North America, Latin America, Europe,
Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity
Analysis, 2018 – 2026
Androgens are male sex hormones
responsible for masculine characteristics such ad muscular build, deeper voice,
and facial hair. Most of the androgens are produced in testes and their two
most common types are dihydrotestosterone (DHT) and testosterone. Along with
normal functions, androgens also contribute to prostate cancer cell growth,
especially during early stages of the cancer. Androgen deprivation therapy,
also called androgen suppression therapy, is used either to reduce the
production of androgens in the patient’s body or to modulate the way androgens
work, thus ultimately inhibiting growth of prostate cancer cells.
Androgen Deprivation Therapy
(ADT) Market Drivers
Key players in the market are
focusing on research to develop new drugs and broaden the indication label of
current drugs for treatment of androgen deprivation therapy (ADT), which is
expected to boost the global androgen deprivation therapy (ADT) market growth
over the forecast period.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2559
For instance, in February 2018,
Janssen Pharmaceutica, a subsidiary of Johnson & Johnson received approval
for its drug ERLEADA (apalutamide) in treatment of non-metastatic
castration-resistant prostate cancer (CRPC). ERLEADA is a next-generation
androgen receptor inhibitor, which belongs to the class of drugs anti-androgens
and blocks the effect of testosterone to slow down the process of tumor growth
and metastasis. It is the first U.S. Food and Drug Administration (FDA)
approved drug for the treatment of patients with non-metastatic CRPC.
Similarly, in July 2018, Pfizer
Inc. and Astellas Pharma Inc. received approval from the U.S. FDA for XTANDI
(enzalutamide) that is indicated for the treatment of non-metastatic CRPC along
with its existing indication for CRPC. XTANDI is an androgen receptor inhibitor
and works by inhibiting the effects of testosterone, thereby slowing tumor
growth and metastasis. These factors are expected to have a positive impact on
the global androgen deprivation therapy (ADT) market growth over the forecast
period.
Androgen Deprivation Therapy
(ADT) Market Regional Analysis
Approval for new drugs is
expected to boost the global androgen deprivation therapy (ADT) market growth
over the forecast period. For instance, in November 2017, European Commission
(EC) granted approval to Janssen-Cilag International NV (Janssen) for
broadening the existing marketing authorization for its drug Zytiga
(abiraterone acetate). The approval enables the company to include the drug in
treatment of metastatic prostate cancer’s early stages along with ADT. Such new
drug approvals are expected to propel Europe androgen deprivation therapy (ADT)
market growth over the forecast period.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/androgen-deprivation-therapy-adt-market-2559
Androgen Deprivation Therapy
(ADT) Market Restraints
According to American Cancer
Society (ASC), several prostate cancers, which are treated with ADT develop
resistance to the treatment over a period of time (few months or years).
Hormone therapy is not useful in treating hormone refractory prostate cancer i.e.
cancer, which is no longer responding to hormone therapy. According to National
Cancer Institute (NCI), National Institutes of Health (NIH), along with
prostate, androgens also contribute to functions of other organs. Therefore,
hormone deprivation therapy is associated with side effects such as hot
flashes, loss of bone density, erectile dysfunction, lowered libido, loss of
muscular strength mass, insulin resistance, and change in blood lipids,
fatigue, mood swings, weight gain and gynecomastia. These factors are expected
to restrain the global androgen deprivation therapy (ADT) market growth over
the forecast period.
Androgen Deprivation Therapy
(ADT) Market Key Players
Some of the major players
operating in the androgen deprivation therapy (ADT) market include, Pfizer
Inc., Astellas Pharma Inc., Johnson & Johnson, Novartis International AG,
Veru Inc., Sanofi S.A., GlaxoSmithKline plc, Bayer AG, Orion Corporation, and
AstraZeneca Plc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2559
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment